SG Americas Securities’s Silence Therapeutics SLN Stock Holding History
Bought
Maintained
Sold
Other funds holding SLN
SL
TCM
RG
NCM
NI
TAM
SCM
SG Americas Securities's SLN Position: Q2 2026 in Review
SG Americas Securities reduced its Silence Therapeutics (SLN) stake by 96% in Q2 2026, selling an estimated $1.93M and leaving 12,056 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #2984.
SG Americas Securities first reported a position in SLN in Q1 2021 and has held it in 19 quarters since. The position peaked at $6.52M in Q2 2024. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.
- SG Americas Securities held 12,056 shares of Silence Therapeutics worth $132K as of Q2 2026.
- SG Americas Securities sold 274,642 Silence Therapeutics shares in Q2 2026, an estimated $1.93M.
- Silence Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #2984 holding.
- SG Americas Securities first reported a position in Silence Therapeutics in Q1 2021 and has held it in 19 quarters since.
- SG Americas Securities's Silence Therapeutics position peaked at $6.52M in Q2 2024.
- 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.
Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.